blank Quick help
blank Maintenance news

Scheduled maintenance

Regular maintenance outages:
between 05.00 and 05.15 hrs CET (Monday to Sunday).

Other outages
Availability
Register Forum

2022.02.11

More...
blank News flashes

News Flashes

New version of the European Patent Register – SPC proceedings information in the Unitary Patent Register.

2024-07-24

More...
blank Related links

Release notes
European Patent Register Assistant
European Patent Register Resource Book
European Patent Register – pocket guide
FAQ - European Patent Register
FAQ - Register Alert
Federated Register (Flyer)
Global Dossier (Flyer)
Register events
Deep link coverage
Federated Register content
The Patent Information Tour
Fair use charter

Extract from the Register of European Patents

EP About this file: EP1476120

EP1476120 - TREATMENT METHODS USING ANTI-CD22 ANTIBODIES [Right-click to bookmark this link]
StatusNo opposition filed within time limit
Status updated on  05.08.2011
Database last updated on 02.09.2024
Most recent event   Tooltip04.10.2013Lapse of the patent in a contracting state
New state(s): HU		published on 06.11.2013  [2013/45]
Applicant(s)For all designated states
Duke University
M454 Davison Building, DUMC Box 3664
Durham, NC 27710 / US
For all designated states
The Regents of the University of California
1111 Franklin Street, 12th Floor
Oakland, CA 94607 / US
[N/P]
Former [2010/39]For all designated states
Duke University
M454 Davison Building, DUMC Box 3664
Durham, NC 27710 / US
For all designated states
The Regents of The University of California
5th floor, 1111 Franklin Street
Oakland, CA 94607-5200 / US
Former [2004/47]For all designated states
Duke University
M454 Davison Building, DUMC Box 3664
Durham, NC 27710 / US
For all designated states
The Regents of The University of California
5th floor, 1111 Franklin Street
Oakland, CA 94607-5200 / US
Inventor(s)01 / TEDDER, Thomas
3000 Wild Meadow Drive
Durham, NC 27705 / US
02 / TUSCANO, Joseph
150 Torndike Way
Folsom, CA 95630 / US
 [2004/47]
Representative(s)Grund, Martin, et al
Grund Intellectual Property Group
Patentanwälte und Solicitor PartG mbB
Steinsdorfstraße 2
80538 München / DE
[N/P]
Former [2006/08]Grund, Martin, et al
GRUND Intellectual Property Group Postfach 44 05 16
80754 München / DE
Former [2004/47]Grund, Martin, Dr., et al
Dr. Volker Vossius, Patentanwaltskanzlei, Geibelstrasse 6
81679 München / DE
Application number, filing date03711190.321.02.2003
[2004/47]
WO2003US05323
Priority number, dateUS20020359419P21.02.2002         Original published format: US 359419 P
US20020420472P21.10.2002         Original published format: US 420472 P
[2004/47]
Filing languageEN
Procedural languageEN
PublicationType: A2 Application without search report
No.:WO03072036
Date:04.09.2003
Language:EN
[2003/36]
Type: A2 Application without search report 
No.:EP1476120
Date:17.11.2004
Language:EN
The application published by WIPO in one of the EPO official languages on 04.09.2003 takes the place of the publication of the European patent application.
[2004/47]
Type: B1 Patent specification 
No.:EP1476120
Date:29.09.2010
Language:EN
[2010/39]
Search report(s)International search report - published on:US31.12.2003
(Supplementary) European search report - dispatched on:EP10.11.2005
ClassificationIPC:A61K39/00, A61K39/395, A61K35/00, C07K16/46, C12N15/13, A61P35/00, // C07K16/28
[2005/52]
CPC:
C07K16/2803 (EP,US); A61K39/395 (KR); A61K39/39533 (EP,US);
A61P1/00 (EP); A61P1/04 (EP); A61P13/02 (EP);
A61P13/12 (EP); A61P17/00 (EP); A61P17/02 (EP);
A61P17/06 (EP); A61P19/00 (EP); A61P19/02 (EP);
A61P19/04 (EP); A61P21/00 (EP); A61P21/04 (EP);
A61P25/00 (EP); A61P27/02 (EP); A61P29/00 (EP);
A61P3/10 (EP); A61P35/00 (EP); A61P35/02 (EP);
A61P37/00 (EP); A61P37/02 (EP); A61P37/04 (EP);
A61P37/06 (EP); A61P37/08 (EP); A61P5/00 (EP);
A61P5/14 (EP); A61P5/16 (EP); A61P7/00 (EP);
A61P7/02 (EP); A61P7/04 (EP); A61P7/06 (EP);
A61P9/00 (EP); A61P9/08 (EP); A61P9/10 (EP);
C07K16/28 (KR); C12N15/11 (KR); A61K2039/505 (EP,US);
C07K2317/56 (EP,US); C07K2317/73 (EP,US); C07K2317/76 (EP,US) (-)
C-Set:
A61K39/39533, A61K2300/00 (EP,US)
Former IPC [2005/49]A61K39/395
Former IPC [2004/47]A61K6/00
Designated contracting statesAT,   BE,   BG,   CH,   CY,   CZ,   DE,   DK,   EE,   ES,   FI,   FR,   GB,   GR,   HU,   IE,   IT,   LI,   LU,   MC,   NL,   PT,   SE,   SI,   SK,   TR [2004/47]
Extension statesALNot yet paid
LTNot yet paid
LVNot yet paid
MKNot yet paid
RONot yet paid
TitleGerman:BEHANDLUNGSVERFAHREN UNTER VERWENDUNG VON ANTI-CD22-ANTIKÖRPERN[2004/47]
English:TREATMENT METHODS USING ANTI-CD22 ANTIBODIES[2004/47]
French:METHODES THERAPEUTIQUES UTILISANT DES ANTICORPS ANTI-CD22[2004/47]
Entry into regional phase04.08.2004National basic fee paid 
04.08.2004Search fee paid 
04.08.2004Designation fee(s) paid 
04.08.2004Examination fee paid 
Examination procedure04.08.2004Amendment by applicant (claims and/or description)
04.08.2004Examination requested  [2004/47]
19.10.2006Despatch of a communication from the examining division (Time limit: M06)
18.04.2007Reply to a communication from the examining division
16.08.2007Despatch of a communication from the examining division (Time limit: M06)
11.02.2008Reply to a communication from the examining division
17.04.2009Despatch of a communication from the examining division (Time limit: M02)
24.06.2009Reply to a communication from the examining division
19.04.2010Communication of intention to grant the patent
18.08.2010Fee for grant paid
18.08.2010Fee for publishing/printing paid
Opposition(s)30.06.2011No opposition filed within time limit [2011/36]
Fees paidRenewal fee
22.02.2005Renewal fee patent year 03
27.02.2006Renewal fee patent year 04
27.02.2007Renewal fee patent year 05
25.02.2008Renewal fee patent year 06
26.06.2009Renewal fee patent year 07
26.04.2010Renewal fee patent year 08
Penalty fee
Additional fee for renewal fee
28.02.200907   M06   Fee paid on   26.06.2009
28.02.201008   M06   Fee paid on   26.04.2010
Opt-out from the exclusive  Tooltip
competence of the Unified
Patent Court		 See the Register of the Unified Patent Court for opt-out data
Responsibility for the accuracy, completeness or quality of the data displayed under the link provided lies entirely with the Unified Patent Court.
Lapses during opposition  TooltipAT29.09.2010
BE29.09.2010
CY29.09.2010
CZ29.09.2010
DK29.09.2010
EE29.09.2010
FI29.09.2010
HU29.09.2010
IT29.09.2010
NL29.09.2010
SE29.09.2010
SI29.09.2010
SK29.09.2010
TR29.09.2010
BG29.12.2010
GR30.12.2010
ES09.01.2011
PT31.01.2011
IE21.02.2011
LU21.02.2011
CH28.02.2011
LI28.02.2011
MC28.02.2011
[2013/45]
Former [2013/44]AT29.09.2010
BE29.09.2010
CY29.09.2010
CZ29.09.2010
DK29.09.2010
EE29.09.2010
FI29.09.2010
IT29.09.2010
NL29.09.2010
SE29.09.2010
SI29.09.2010
SK29.09.2010
TR29.09.2010
BG29.12.2010
GR30.12.2010
ES09.01.2011
PT31.01.2011
IE21.02.2011
LU21.02.2011
CH28.02.2011
LI28.02.2011
MC28.02.2011
Former [2013/42]AT29.09.2010
BE29.09.2010
CY29.09.2010
CZ29.09.2010
DK29.09.2010
EE29.09.2010
FI29.09.2010
IT29.09.2010
NL29.09.2010
SE29.09.2010
SI29.09.2010
SK29.09.2010
BG29.12.2010
GR30.12.2010
ES09.01.2011
PT31.01.2011
IE21.02.2011
LU21.02.2011
CH28.02.2011
LI28.02.2011
MC28.02.2011
Former [2013/26]AT29.09.2010
BE29.09.2010
CY29.09.2010
CZ29.09.2010
DK29.09.2010
EE29.09.2010
FI29.09.2010
IT29.09.2010
NL29.09.2010
SE29.09.2010
SI29.09.2010
SK29.09.2010
GR30.12.2010
ES09.01.2011
PT31.01.2011
IE21.02.2011
LU21.02.2011
CH28.02.2011
LI28.02.2011
MC28.02.2011
Former [2013/25]AT29.09.2010
BE29.09.2010
CZ29.09.2010
DK29.09.2010
EE29.09.2010
FI29.09.2010
IT29.09.2010
NL29.09.2010
SE29.09.2010
SI29.09.2010
SK29.09.2010
GR30.12.2010
ES09.01.2011
PT31.01.2011
IE21.02.2011
LU21.02.2011
CH28.02.2011
LI28.02.2011
MC28.02.2011
Former [2012/08]AT29.09.2010
BE29.09.2010
CZ29.09.2010
DK29.09.2010
EE29.09.2010
FI29.09.2010
IT29.09.2010
NL29.09.2010
SE29.09.2010
SI29.09.2010
SK29.09.2010
GR30.12.2010
ES09.01.2011
PT31.01.2011
IE21.02.2011
CH28.02.2011
LI28.02.2011
MC28.02.2011
Former [2011/48]AT29.09.2010
BE29.09.2010
CZ29.09.2010
DK29.09.2010
EE29.09.2010
FI29.09.2010
IT29.09.2010
NL29.09.2010
SE29.09.2010
SI29.09.2010
SK29.09.2010
GR30.12.2010
ES09.01.2011
PT31.01.2011
CH28.02.2011
LI28.02.2011
MC28.02.2011
Former [2011/45]AT29.09.2010
BE29.09.2010
CZ29.09.2010
DK29.09.2010
EE29.09.2010
FI29.09.2010
IT29.09.2010
NL29.09.2010
SE29.09.2010
SI29.09.2010
SK29.09.2010
GR30.12.2010
ES09.01.2011
PT31.01.2011
MC28.02.2011
Former [2011/40]AT29.09.2010
BE29.09.2010
CZ29.09.2010
DK29.09.2010
EE29.09.2010
FI29.09.2010
IT29.09.2010
NL29.09.2010
SE29.09.2010
SI29.09.2010
SK29.09.2010
GR30.12.2010
ES09.01.2011
PT31.01.2011
Former [2011/35]AT29.09.2010
BE29.09.2010
CZ29.09.2010
EE29.09.2010
FI29.09.2010
IT29.09.2010
NL29.09.2010
SE29.09.2010
SI29.09.2010
SK29.09.2010
GR30.12.2010
ES09.01.2011
PT31.01.2011
Former [2011/31]AT29.09.2010
BE29.09.2010
CZ29.09.2010
EE29.09.2010
FI29.09.2010
IT29.09.2010
NL29.09.2010
SE29.09.2010
SI29.09.2010
SK29.09.2010
GR30.12.2010
PT31.01.2011
Former [2011/24]AT29.09.2010
CZ29.09.2010
EE29.09.2010
FI29.09.2010
NL29.09.2010
SE29.09.2010
SI29.09.2010
SK29.09.2010
GR30.12.2010
PT31.01.2011
Former [2011/23]AT29.09.2010
CZ29.09.2010
EE29.09.2010
FI29.09.2010
SE29.09.2010
SI29.09.2010
SK29.09.2010
GR30.12.2010
Former [2011/15]AT29.09.2010
FI29.09.2010
SE29.09.2010
SI29.09.2010
GR30.12.2010
Former [2011/10]AT29.09.2010
FI29.09.2010
SI29.09.2010
Former [2011/08]AT29.09.2010
Documents cited:Search[DX]US5484892  (TEDDER THOMAS F [US], et al) [DX] 1-43 * column 3, line 4 - line 42 * * column 5, line 61 - line 67 * * column 6, line 1 - line 7 * * column 8, line 57 - line 62 * * column 10, line 28 - line 67 * * column 11, line 1 - line 17 * * column 16, line 8 - line 11 * * column 16, line 33 - line 35 * * tables II,III,IV,V *;
 [L]WO03072736  (UNIV DUKE [US], et al) [L] 1-43* the whole document *;
 [X]  - LEONARD J P ET AL, "EPRATUZUMAB, A NEW ANTI-CD22. HUMANIZED, MONOCLONAL ANTIBODY FOR THE THERAPY OF NON-HODGKIN'S LYMPHOMA (NHL): PHASE I/II TRIAL RESULTS", BLOOD, W.B. SAUNDERS, PHILADELPHIA, VA, US, (19991115), vol. 94, no. 10 SUPPL PART 1, ISSN 0006-4971, pages 92A - 93A, XP000929541 [X] 1-39 * the whole document *
 [A]  - STEIN R ET AL, "EPITOPE SPECIFICITY OF THE ANTI-(B CELL LYMPHOMA) MONOCLONAL ANTIBODY LL2", CANCER IMMUNOLOGY AND IMMUNOTHERAPY, BERLIN, DE, (1993), vol. 37, no. 5, ISSN 0340-7004, pages 293 - 298, XP002070322 [A] 1-39 * page 296, column RIGHT, line 3 - line 27 *

DOI:   http://dx.doi.org/10.1007/BF01518451
International search[Y]US5484892  (TEDDER THOMAS F [US], et al)
Examination   - CARNAHAN JOSETTE ET AL, "Epratuzumab, a humanized monoclonal antibody targeting CD22: characterization of in vitro properties.", CLINICAL CANCER RESEARCH : AN OFFICIAL JOURNAL OF THE AMERICAN ASSOCIATION FOR CANCER RESEARCH 1 SEP 2003, (20030901), vol. 9, no. 10 Pt 2, ISSN 1078-0432, pages 3982S - 90S
    - LEONARD JOHN P ET AL, "Phase I/II trial of epratuzumab (humanized anti-CD22 antibody) in indolent non-Hodgkin's lymphoma.", JOURNAL OF CLINICAL ONCOLOGY : OFFICIAL JOURNAL OF THE AMERICAN SOCIETY OF CLINICAL ONCOLOGY 15 AUG 2003, (20030815), vol. 21, no. 16, ISSN 0732-183X, pages 3051 - 3059
by applicant   - "EPRATUZUMAB, A NEW ANTI-CD22, HUMANIZED, MONOCLONAL ANTIBODY FOR THE THERAPY OF NON-HODGKIN'S LYMPHOMA and PHASE I/II TRIAL RESULTS", LEONARD J P ET AL., BLOOD, W.B. SAUNDERS, (19991115), vol. 94, pages 92A - 93A
The EPO accepts no responsibility for the accuracy of data originating from other authorities; in particular, it does not guarantee that it is complete, up to date or fit for specific purposes.